Dhvanit Shah, Garuda Therapeutics CEO
Blood stem cell therapy maker Garuda nabs $62M
Garuda Therapeutics brought in $62 million via a Series B to take its off-the-shelf cell therapies into the clinic next year.
The Boston-area biotech wants to rid the need for blood stem cell transplants and instead give patients self-renewing blood stem cells. The proceeds, which add to a $72 million Series A from September 2021, will bankroll two lead programs in hematological and oncology indications, Garuda said Tuesday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
